8KMDGLTier 5
기사 목록MADRIGAL PHARMACEUTICALS, INC. 8K
0001628280-26-055962
View on SEC EDGARMadrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., to its Board of Directors to strengthen its scientific and R&D leadership.
Madrigal Pharmaceuticals, Inc. announced that it has appointed John C. Reed, M.D., Ph.D., currently Executive Vice President, Innovative Medicine, Research & Development and a member of the Executive Committee at Johnson & Johnson, to its Board of Directors, citing his extensive experience leading global R&D organizations and advancing innovative medicines as an important asset to support Madrigal’s continued growth, the launch and commercialization of Rezdiffra, and the advancement of its MASH pipeline.
Filing Facts
- CIK
- 1157601
- Ticker
- MDGL
- Form
- 8K
- Source Type
- fda
- Accession
- 0001628280-26-055962
- Alert Tier
- 5